Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,393,625 papers from all fields of science
Search
Sign In
Create Free Account
GC33
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Anti-GPC3 Monoclonal Antibody GC33
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract 2747: Anti-glypican-3 monoclonal antibody (codrituzumab/GC33/RO5137382) treatment enhances tumor infiltration of PD-L1-positive macrophages, and combination therapy with anti-PD-L1…
M. Endo
,
Yasuko Kinoshita
,
+7 authors
T. Ohtomo
Immunology
2018
Corpus ID: 56875413
Introduction: Codrituzumab/GC33/RO5137382 (GC33) is a humanized monoclonal antibody that targets glypican-3 (GPC3), an oncofetal…
Expand
Highly Cited
2014
Highly Cited
2014
Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma
M. Ikeda
,
S. Ohkawa
,
+6 authors
J. Furuse
Cancer Science
2014
Corpus ID: 17158607
GC33 is a humanized mAb against human glypican‐3 (GPC3). In the first‐in‐human study carried out in the USA, GC33 was well…
Expand
2014
2014
Phase Ib study of RO5137382/GC33 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC) (NCT00976170).
G. Abou-Alfa
,
C. Yen
,
+17 authors
A. Cheng
2014
Corpus ID: 78609240
4100 Background: GC33 is a recombinant humanized monoclonal antibody against Glypican-3 (GPC3) which is highly expressed in HCC…
Expand
2014
2014
Biomarker analysis of a randomized, placebo-controlled, double-blind, multicenter phase II trial of intravenous RO5137382/GC33 at 1600 mg Q2W in previously treated patients with unresectable advanced…
O. Puig
,
Ya-Chi Chen
,
+16 authors
R. Lee
2014
Corpus ID: 78745832
e15090 Background: Glypican-3 (GPC3) is an oncofetal protein frequently expressed in HCC. GC33 is a humanized monoclonal antibody…
Expand
2013
2013
A phase I study of GC33 in Japanese patients with advanced hepatocellular carcinoma (HCC).
T. Okusaka
,
M. Ikeda
,
S. Ohkawa
,
Shunsuke Yamamoto
,
Ikue Suzuki
,
J. Furuse
2013
Corpus ID: 78215819
235 Background: Glypican-3 (GPC3) belongs to a family of cell-surface heparan sulfate proteoglycans and is specifically expressed…
Expand
2011
2011
A phase I study of GC33, a recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma (HCC).
A. Zhu
,
P. Gold
,
+4 authors
P. Philip
Journal of Clinical Oncology
2011
Corpus ID: 6034154
4085 Background: Glypican 3 (GPC3) belongs to a family of cell-surface heparan sulfate proteoglycans and is specifically…
Expand
2009
2009
Histopathological analyses of the antitumor activity of anti-glypican-3 antibody (GC33) in human liver cancer xenograft models: The contribution of macrophages.
H. Takai
,
A. Kato
,
+5 authors
Masami Suzuki
Cancer Biology & Therapy
2009
Corpus ID: 45319523
Previously, we demonstrated the antitumor efficacy of the anti-glypican-3 (GPC3) antibody GC33 in several human liver cancer…
Expand
2008
2008
Human Liver Cancer Glypican 3 Antibody as a Potential Antitumor Agent for − Anti
Takahiro Ishiguro
,
Masamichi Sugimoto
,
+10 authors
H. Yamada‐Okabe
2008
Corpus ID: 207786622
Human glypican 3 (GPC3) is preferentially expressed in the tumor tissues of liver cancer patients. In this study, we obtained a…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE
or Only Accept Required